Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OM 8980

Drug Profile

OM 8980

Alternative Names: Escherichia coli extract (ECE) - Vifor Pharma; OM 89; OM-8980; SolcoUrovac; Subreum; Uro-Vaxom

Latest Information Update: 04 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OM Pharma
  • Developer Apsen Farmaceutica; Eurolab Especialidades Medicinales de Eurofar; Tosse Pharmaceuticals; Vifor Pharma
  • Class Antirheumatics; Bacterial vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis; Urinary tract infections
  • No development reported Prostatitis
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 06 Dec 2012 Invida is now called Menarini Asia-Pacific
  • 11 Nov 2011 Invida Group has been acquired by Menarini
  • 09 Sep 2009 OM Pharma has been acquired and merged into Vifor Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top